PF4V1 蛋白, Human (HEK293, Fc)

PF4V1, also known as CXCL4L1, is a non-allelic variant of CXCL4. PF4V1 is a platelet-associated chemokine, and it binds to heparin is much weaker than in the close homolog PF4/CXCL4. PF4V1 is an inhibitor of angiogenesis and inhibitor of endothelial cell chemotaxis. PF4V1 is involved in inflammation, angiogenesis, and cancer^[1][2]. PF4V1 Protein, Human (HEK293, Fc) is produced in HEK293 cells with a C-Terminal Fc-tag. It consists of 104 amino acids (M1-S104).

PF4V1 (CXCL4L1) 是一种 CXC 趋化因子，最初是从凝血酶刺激的血小板中分离出来的。全长人 CXCL4L1/PF-4var 由 104 个氨基酸组成。CXCL4L1 似乎由血小板、平滑肌细胞、人主动脉和冠状动脉平滑肌细胞组成性释放，并且可在单核细胞、内皮细胞和骨肉瘤细胞中被炎症介质诱导。CXCL4L1 在炎症、血管生成和癌症中发挥作用^[1][2][3]。
CXCL4 及其非等位变体 CXCL4L1 都是血小板衍生的趋化因子。成熟的 CXCL4L1 蛋白由 70 个氨基酸组成，差异仅在于位于蛋白羧基末端部分的 3 个氨基酸 (Pro58 ) Leu、Lys66 ) Glu、Leu67 ) His；CXCL4) CXCL4L1)。由于氨基酸的这些变化，CXCL4L1 被认为具有不同的二级结构和对肝素较低的亲和力。在体内，通过免疫组织化学检测肉瘤组织中CXCL4L1的弱到强表达。CXCL4L1 作为活化 T 细胞、NK 细胞和未成熟树突状细胞的化学引诱剂。与 CXCL4 相比，CXCL4L1 是一种更有效的血管抑制趋化因子。与 CXCL4 相比，CXCL4L1 不太可能与 fFGF2 和 VEGF 形成异二聚体或竞争 GAG 结合^{[1][2][3]IL-17A 诱导。CXCL4L1 在多种癌症中表达并发挥作用，例如卵巢癌、乳腺癌和胰腺癌。此外，结直肠癌组织样本中也强烈检测到 CXCL4L1，而食管鳞状细胞癌中的 CXCL4L1 染色较弱甚至呈阴性[1][2] [3]。}

Recombinant human CXCL4L1 protein (3, 1 or 3 ng/mL; for 2 hours) inhibits signal transduction and migration of human microvascular endothelial cells towards VEGF and FGF-2 in HMVEC. Recombinant human CXCL4L1 (1 ng/mL; for 5 min) protein counteracts FGF-2-induced ERK phosphorylation in HMVEC^[4].

Recombinant human PF4V1 protein (25 µg/mous; intratumorally injection; three times per week; for 21 days) suppresses the growth of prostate cancer in nude mice model^[2].

Measured by its ability to inhibit proliferation of HUVEC human umbilical vein endothelial cells. The ED₅₀ of this effect is 37.49 ng/mL, corresponding to a specific activity is 2.67×10⁴ units/mg.

• 
  Measured by its ability to inhibit proliferation of HUVEC human umbilical vein endothelial cells. The ED₅₀ of this effect is 37.49 ng/ml, corresponding to a specific activity is 2.67×10⁴ units/mg.

Human

HEK293

C-mFc

NP_002611.1 (F31-S104)

5197  [NCBI]

FARAEAEEDGDLQCLCVKTTSQVRPRHITSLEVIKAGPHCPTAQLIATLKNGRKICLDLQALLYKKIIKEHLES

Approximately38.69 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末.

Lyophilized from a 0.2 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Pieter Ruytinx, et al. CXCL4 and CXCL4L1 in cancer. Cytokine. 2018 Sep;109:65-71.  [Content Brief]

  [2]. Dongyang Li, et al. PF4V1, an miRNA-875-3p target, suppresses cell proliferation, migration, and invasion in prostate cancer and serves as a potential prognostic biomarker. Cancer Manag Res. 2019 Mar 21;11:2299-2312.  [Content Brief]

  [3]. Jo Vandercappellen, et al. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev. 2011 Feb;22(1):1-18.  [Content Brief]

  [4]. Pieter Ruytinx, et al. Relative distribution and biological characterization of CXCL4L1 isoforms in platelets from healthy donors. Biochem Pharmacol. 2017 Dec 1;145:123-131.  [Content Brief]